Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Sartore-Bianchi, Andrea

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Oct 2007 - 5942-51 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1078-0432

10.1158/1078-0432.CCR-07-0536 doi


Animals
Antineoplastic Agents--pharmacology
Boronic Acids--pharmacology
Bortezomib
Cell Line, Tumor
Cell Survival
Cell Transformation, Neoplastic
Enzyme Inhibitors--pharmacology
Humans
Male
Mesothelioma--drug therapy
Mice
Mice, Nude
NF-kappa B--metabolism
Nitriles--pharmacology
Proteasome Inhibitors
Pyrazines--pharmacology
Sulfones--pharmacology
Tumor Necrosis Factor-alpha--metabolism